Furthermore, the inhibitory assay showed that only the γ-secretase inhibitor of DAPT reduces GFAP levels and decreases brain infarct volume, suggesting γ-secretase appears to be a therapeutic target and its inhibitor of DAPT may have the therapeutic potential for the treatment of stroke. Here, GFAP is linked to Stroke.